Cost and cost‐effectiveness analysis of pre‐exposure prophylaxis among men who have sex with men in two hospitals in Thailand

• Published in: Journal of the International AIDS Society 2018-07, Vol.21 (S5), p.e25129-n/a
• Main Authors: Suraratdecha, Chutima, Stuart, Robyn M, Manopaiboon, Chomnad, Green, Dylan, Lertpiriyasuwat, Cheewanan, Wilson, David P, Pavaputanon, Patcharaporn, Visavakum, Prin, Monkongdee, Patama, Khawcharoenporn, Thana, Tharee, Phiphatthananon, Kittinunvorakoon, Chonticha, Martin, Michael
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; AIDS; Analysis; Antiviral agents; Condoms; cost; Cost analysis; Cost benefit analysis; Cost control; cost‐effectiveness analysis; Counseling; Disease control; Disease prevention; Drug therapy; Drugs; Economic aspects; Health aspects; Highly active antiretroviral therapy; HIV; HIV infection; HIV infections; Hospitals; Human immunodeficiency virus; Medical care, Cost of; Medical laboratories; Medical tests; modelling; MSM (Men who have sex with men); Prevention; pre‐exposure prophylaxis; Prophylaxis; Public health; Statistics; Studies; Thailand; Womens health
• ISSN: 1758-2652; 1758-2652
• DOI: 10.1002/jia2.25129

Introduction In 2014, the Government of Thailand recommended pre‐exposure prophylaxis (PrEP) as an additional HIV prevention programme within Thailand's National Guidelines on HIV/AIDS Treatment Prevention. However, to date implementation and uptake of PrEP programmes have been limited, and evidence on the costs and the epidemiological and economic impact is not available. Methods We estimated the costs associated with PrEP provision among men having sex with men (MSM) participating in a facility‐based, prospective observational cohort study: the Test, Treat and Prevent HIV Programme in Thailand. We created a suite of scenarios to estimate the cost‐effectiveness of PrEP and sensitivity of the results to the model input parameters, including PrEP programme effectiveness, PrEP uptake among high‐risk and low‐risk MSM, baseline and future antiretroviral therapy (ART) coverage, condom use, unit cost of delivering PrEP, and the discount rate. Results Drug costs accounted for 82.5% of the total cost of providing PrEP, followed by lab testing (8.2%) and personnel costs (7.8%). The estimated costs of providing the PrEP package in accordance with the national recommendation ranges from US$223 to US$311 per person per year. Based on our modelling results, we estimate that PrEP would be cost‐effective when provided to either high‐risk or all MSM. However, we found that the programme would be approximately 32% more cost‐effective if offered to high‐risk MSM than it would be if offered to all MSM, with an incremental cost‐effectiveness ratio of US$4,836 per disability‐adjusted life years (DALY) averted and US$7,089 per DALY averted respectively. Cost‐effectiveness acceptability curves demonstrate that 80% of scenarios would be cost‐effective when PrEP is provided solely to higher‐risk MSM. Conclusion We provide the first estimates on cost and cost‐effectiveness of PrEP in the Asia‐Pacific region, and offer insights on how to deliver PrEP in combination with ART. While the high drug cost poses a budgeting challenge, incorporating PrEP delivery into an existing ART programme could be a cost‐effective strategy to prevent HIV infections among MSM in Thailand.